Details:

Personal Author:
Clarke, Kristie E. N. ; Jones, Jefferson M. ; Deng, Yangyang ; Nycz, Elise ; Lee, Adam ; ... More +
Clarke, Kristie E. N. ; Jones, Jefferson M. ; Deng, Yangyang ; Nycz, Elise ; Lee, Adam ; Iachan, Ronaldo ; Gundlapalli, Adi V. ; Hall, Aron J. ; MacNeil, Adam Less -
Corporate Authors:
CDC COVID-19 Emergency Response Team ; ICF International
CDC COVID-19 Emergency Response Team ; ICF International Less -
Description:
In December 2021, the B.1.1.529 (Omicron) Variants of SARS-CoV-2, the Virus that causes COVID-19, became predominant in the U.S. Subsequently, national COVID-19 case rates peaked at their highest recorded levels. Traditional Methods of disease Surveillance do not capture all COVID-19 cases because some are asymptomatic, not diagnosed, or not reported; therefore, the proportion of the population with SARS-CoV-2 antibodies (i.e., seroprevalence) can improve understanding of population-level incidence of COVID-19. This report uses data from CDC’s national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. Trends in infection-induced SARS-CoV-2 seroprevalence during September 2021–February 2022, by age group.

The national commercial laboratory seroprevalence study is a repeated, cross-sectional, national survey that estimates the proportion of the population in 50 U.S. states, the District of Columbia, and Puerto Rico that has infection-induced antibodies to SARS-CoV-2.† Sera are tested for anti-nucleocapsid (anti-N) antibodies, which are produced in response to infection but are not produced in response to COVID-19 vaccines currently authorized for emergency use or approved by the Food and Drug Administration in the U.S.

Suggested citation for this article: Clarke KE, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — U.S. September 2021–February 2022. MMWR Morb Mortal Wkly Rep 2022;71.

mm7117e3.htm?s_cid=mm7117e3_w

mm7117e3-H.pdf


Subjects:
[+]
Antibodies, Viral/blood COVID-19 COVID-19 Serological Testing SARS-CoV-2 Seroepidemiologic Studies
Series:
MMWR; v. 71, ER, 4/26/22
Document Type:
Journal Article
Place as Subject:
U.S.
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:acb81e1e45878e06b623b07d1847da5031016a0bd936dad6fb5c4a0b95b70e9a
Download URL:
https://stacks.cdc.gov/view/cdc/116722/cdc_116722_DS1.pdf
File Type:

Supporting Files

• mm7117e3.htm

  htm

More +